

Oncology Today with Dr Neil Love: Optimizing the Selection of First-Line and Maintenance Therapy for Patients with Extensive-Stage Small Cell Lung Cancer

THE CORRECT ANSWER IS INDICATED WITH YELLOW HIGHLIGHTING.

1. Which of the following efficacy outcomes best represents results from the Phase III IMforte trial evaluating first-line maintenance therapy with lurbinectedin/atezolizumab after induction therapy with atezolizumab/carboplatin/etoposide for patients with previously untreated extensive-stage small cell lung cancer (ES-SCLC)?
  - a. A numerical but nonsignificant improvement in progression-free survival (PFS) and overall survival (OS)
  - b. A significant improvement in PFS and a numerical but nonsignificant improvement in OS
  - c. A statistically significant improvement in both PFS and OS
2. What was the rate of 36-month OS with the addition of durvalumab to first-line chemotherapy for patients with ES-SCLC in the Phase III CASPIAN trial?
  - a. 2.6%
  - b. 4.6%
  - c. 8.6%
  - d. 17.6%
3. Small cell lung cancer accounts for approximately what proportion of all lung cancer?
  - a. 5%
  - b. 15%
  - c. 40%
4. What was the approximate rate of discontinuation due to adverse events with lurbinectedin/atezolizumab maintenance therapy in the Phase III IMforte trial?
  - a. 0%
  - b. 6%
  - c. 20%
5. What was the approximate median OS with lurbinectedin/atezolizumab maintenance therapy in the Phase III IMforte trial?
  - a. 6 months
  - b. 13 months
  - c. 20 months